Clinical Trial Update: EG-501 for Cognitive Impairment in Neuropsychiatric SLE (NPSLE): Efficacy and Safety Study [Phase 2]

View source ↗

Summary

Phase 2 study of EG-501 in cognitive impairment associated with neuropsychiatric lupus has completed, evaluating efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuropsychiatric Systemic Lupus Erythematosus
• Systemic Lupus Erythematosus

Drugs mentioned

• EG-501

Snippet

Sponsor: Evergreen Therapeutics, Inc. | Conditions: Neuropsychiatric Systemic Lupus Erythematosus, Systemic Lupus Erythematosus (SLE) | Phase 2 | Status: COMPLETED